Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.43 |
| ▸ | KLK1 | P06870 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxytoluic Acid SCHEMBL29380596 | 1.00 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| Hydroxytoluic Acid SCHEMBL29975592 | 0.96 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| Hydroxytoluic Acid SCHEMBL622891 | 0.96 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| Hydroxytoluic Acid SCHEMBL31175008 | 0.96 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| Hydroxytoluic Acid SCHEMBL29975360 | 0.96 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| Hydroxytoluic Acid SCHEMBL9418192 | 0.96 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| Hydroxytoluic Acid SCHEMBL29975309 | 0.96 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| Hydroxytoluic Acid SCHEMBL416477 | 0.96 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| Hydroxytoluic Acid SCHEMBL4389834 | 0.96 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| Hydroxytoluic Acid SCHEMBL8929635 | 0.87 | ALDH1A1 (0.69) | ALDH1A1KDM4EHPGDHSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4613745-A2 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | Gilead Sciences, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| CN-119661545-A | Preparation method and application of metal phthalocyanine compound with high-efficiency photothermal conversion capability | 浙江理工大学 | 2025-03-21 | — | — | CN | claimed |
| CN-115397824-B | Process for preparing COT inhibitor compounds | 吉利德科学公司 | 2024-10-22 | — | — | CN | claimed |
| CN-117024354-B | Preparation method of Rui Mi Buti Ni | 天津凯莱英制药有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-117164875-A | Preparation method of tubular metal copper phthalocyanine polymer and cyclic carbonate | 浙江理工大学 | 2023-12-05 | — | — | CN | claimed |
| CN-117024354-A | Preparation method of Rui Mi Buti Ni | 天津凯莱英制药有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-114989399-B | Room temperature Suzuki cross-coupling polymerization method of conjugated polymer semiconductor material | 中国科学院大学 | 2023-08-01 | — | — | CN | claimed |
| EP-4126862-A1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | GILEAD SCIENCES, INC. (US) | 2023-02-08 | — | — | EP | claimed |
| CN-115397824-A | Process for preparing COT inhibitor compounds | 吉利德科学公司 | 2022-11-25 | — | — | CN | claimed |
| WO-2021202688-A1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | GILEAD SCIENCES, INC. (US) | 2021-10-07 | — | — | WO | claimed |
| US-20100197954-A1 | SYNTHESIS OF SPHINGOSINES AND THEIR DERIVATIVES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-08-05 | — | — | US | claimed |
| WO-2008030840-A2 | SYNTHESIS OF SPHINGOSINES AND THEIR DERIVATIVES | EMORY UNIVERSITY (US) | 2008-03-13 | — | — | WO | claimed |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| EP-4724070-A2 | WRN INHIBITORS | Nimbus Wadjet, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12600717-B2 | Tricyclic compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2026-04-14 | — | — | US | disclosed |
| US-12528806-B2 | WRN inhibitors | NIMBUS WADJET, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| WO-2010090767-A2 | ENHANCING BIOCOMPATIBILITY OF A MEDICAL DEVICE | ST. JUDE MEDICAL, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010085547-A2 | METHODS OF PREPARING 1-DEOXY-SPHINGOID BASES AND DERIVATIVES THEREOF | EMORY UNIVERSITY (US) | 2010-07-29 | — | — | WO | disclosed |
| US-6969716-B2 | 5-phenyl[1,2,4]triazines as ligands for GABA-A α2/α3 receptors for treating anxiety or depression | MERCK SHARP & DOHME LTD. | 2005-11-29 | — | — | US | disclosed |
| US-20040192692-A1 | 5-Phenyl[1,2,4]triazines as ligands for GABA-A alpha2/alpha3 receptors for treating anxiety or depression | MERCK SHARP & DOHME, LTD. (GB) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600717-B2 | Tricyclic compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | ALDH1A1 2111/4885KDM4E 3998/4885HPGD 2720/4885 |
| US-20040192692-A1 | 5-Phenyl[1,2,4]triazines as ligands for GABA-A alpha2/alpha3 receptors for treating anxiety or depression | GABRA1, GABRA5, GABRA2 | ALDH1A1 260/4885KDM4E 3163/4885HPGD 1721/4885 |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | IRAK3, IKBKB, IKBKG | ALDH1A1 3824/4885KDM4E 1798/4885HPGD 1972/4885 |
| US-12528806-B2 | WRN inhibitors | WRN, RECQL, BLM | ALDH1A1 1817/4885KDM4E 1099/4885HPGD 1748/4885 |
| US-20100197954-A1 | SYNTHESIS OF SPHINGOSINES AND THEIR DERIVATIVES | SPHK1, SPHK2, S1PR2 | ALDH1A1 2912/4885KDM4E 1397/4885HPGD 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.